ITOS250117C18000
- 0.25
- 0.000.00%
ITeos Therapeutics Newsroom
Wells Fargo Maintains ITeos Therapeutics(ITOS.US) With Buy Rating, Cuts Target Price to $19
Wells Fargo Maintains Overweight on ITeos Therapeutics, Lowers Price Target to $19
ITeos Therapeutics Price Target Maintained With a $21.00/Share by HC Wainwright & Co.
H.C. Wainwright Maintains ITeos Therapeutics(ITOS.US) With Buy Rating, Cuts Target Price to $21
ITeos Therapeutics Analyst Ratings
Strategic Focus on Belrestotug Drives Buy Rating for ITeos Therapeutics With Adjusted Price Target of $21
ITeos Therapeutics Analyst Ratings
H.C. Wainwright Maintains ITeos Therapeutics(ITOS.US) With Buy Rating, Maintains Target Price $46
Leerink Partners Maintains ITeos Therapeutics(ITOS.US) With Buy Rating
Wells Fargo Maintains ITeos Therapeutics(ITOS.US) With Buy Rating, Maintains Target Price $31
Strategic Catalysts and Financial Stability Underpin Buy Rating for ITeos Therapeutics
Wells Fargo Maintains ITeos Therapeutics(ITOS.US) With Buy Rating, Maintains Target Price $31
ITeos Therapeutics Analyst Ratings
Piper Sandler Maintains ITeos Therapeutics(ITOS.US) With Buy Rating, Maintains Target Price $36
ITeos Therapeutics (ITOS) Receives a Buy From Piper Sandler
H.C. Wainwright Maintains ITeos Therapeutics(ITOS.US) With Buy Rating, Maintains Target Price $46
Wedbush Raises Price Target on ITeos Therapeutics to $25 From $21, Keeps Outperform Rating
Wells Fargo Maintains ITeos Therapeutics(ITOS.US) With Buy Rating, Maintains Target Price $31
Buy Rating Affirmed for ITeos Therapeutics Amid Promising Lung-201 Study Outcomes
J.P. Morgan Sticks to Its Buy Rating for ITeos Therapeutics (ITOS)